B1 Cont'd

lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:144.

6. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 4-9 consecutive amino acids of SEQ ID NO:144.

B2

7. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 8-9 consecutive amino acids of SEQ ID NO:144.

Please add new claims 46-60 to read as follows:

46. (New) The polypeptide of claim 1, wherein said immunogenic portion differs from SEQ ID NO:144 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

B3

47. (New) A composition comprising any one of the polypeptides of claim 1 or claim 46 in combination with a pharmaceutically acceptable carrier or excipient.

48. (New) An immunogenic composition comprising any one of the polypeptides of claim 1 or claim 46 in combination with a non-specific immune response enhancer.

49. (New) The immunogenic composition according to claim 48 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

50. (New) The composition according to claim 48, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants,

Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

51. (New) The composition of claim 50, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.

52. (New) An isolated polypeptide consisting of an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide consists of no more than amino acids 1-249 of WT1 and wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:144.

53. (New) The polypeptide according to claim 52, wherein the polypeptide consists of 9-16 consecutive amino acids of WT1 and comprises SEQ ID NO:144.

54. (New) The polypeptide according to claim 52, wherein the polypeptide consists of 9-10 consecutive amino acids of WT1 and comprises SEQ ID NO:144.

55. (New) The polypeptide of claim 52, wherein said immunogenic portion differs from WT1 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

56. (New) A composition comprising any one of the polypeptides of claim 52 or claim 55 in combination with a pharmaceutically acceptable carrier or excipient.

57. (New) An immunogenic composition comprising any one of the polypeptides of claim 52 or claim 55 in combination with a non-specific immune response enhancer.